? Recent literature on cannabinoid hyperemesis syndrome, prenatal cannabis exposure, and THC blood testing highlights the growing clinical challenge of managing cannabis-related conditions in an era of increased potency and changing legal status. While CHS presentations are becoming more recognizable and prenatal exposure risks better characterized, the evidence remains complicated by heterogeneous study populations, recall bias in exposure assessment, and the confounding effects of polysubstance use that are rarely adequately controlled in observational research. Blood THC concentrations continue to show poor correlation with clinical effects or recency of use due to high lipophilicity and variable metabolism across individuals, limiting their utility for impairment assessment or exposure timing despite their frequent clinical application. Providers should maintain a high index of suspicion for CHS in heavy cannabis users presenting with cyclical vomiting unresponsive to standard antiemetics, counsel pregnant patients that current evidence suggests prenatal cannabis exposure carries potential

Clinical Perspective

Cannabinoid hyperemesis syndrome represents an increasingly recognized adverse effect pattern that warrants clinical attention, particularly as cannabis potency and consumption frequency continue to rise. Clinicians should maintain awareness of CHS presentation, including intractable nausea and vomiting that paradoxically improves with cessation or reduction of use, to avoid unnecessary diagnostic workup and facilitate appropriate management. Monitoring this condition’s epidemiology and clinical characteristics remains important as cannabis use patterns evolve across diverse patient populations.